188 related articles for article (PubMed ID: 22199315)
21. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
22. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
24. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
25. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
26. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
27. IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
Zhang XQ; Kiang KM; Wang YC; Pu JK; Ho A; Cheng SY; Lee D; Zhang PD; Chen JJ; Lui WM; Fung CF; Leung GK
J Neurooncol; 2015 Nov; 125(2):253-63. PubMed ID: 26337623
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
29. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
30. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Fukunaga T; Fujita Y; Kishima H; Yamashita T
PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
[TBL] [Abstract][Full Text] [Related]
31. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Hasselbalch B; Eriksen JG; Broholm H; Christensen IJ; Grunnet K; Horsman MR; Poulsen HS; Stockhausen MT; Lassen U
APMIS; 2010 Aug; 118(8):585-94. PubMed ID: 20666740
[TBL] [Abstract][Full Text] [Related]
33. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
[TBL] [Abstract][Full Text] [Related]
35. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
36. Friend or foe-IDH1 mutations in glioma 10 years on.
Huang LE
Carcinogenesis; 2019 Nov; 40(11):1299-1307. PubMed ID: 31504231
[TBL] [Abstract][Full Text] [Related]
37. Detection of IDH1 mutation in the plasma of patients with glioma.
Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
[TBL] [Abstract][Full Text] [Related]
38. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
Scott BJ; Quant EC; McNamara MB; Ryg PA; Batchelor TT; Wen PY
Neuro Oncol; 2010 Jun; 12(6):603-7. PubMed ID: 20156808
[TBL] [Abstract][Full Text] [Related]
40. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]